# Surgical Oncology (breast) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Richard Roundtree (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML015-SYN
- Date: 2026-10-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Farah Siddiqui, MD
- Calendar frame: modern shifted

- Requested by: Leon Carrington, MD

## Reason for consultation

Man of 51 with a new 1.5 cm firm, painless lump eccentric to the left nipple and a palpable left axillary node; breast cancer suspected. Diagnostic mammography, ultrasound, and core biopsy are booked for tomorrow. Please see him as soon as the results are back to plan surgery. **S**

## History

Mr. Roundtree is seen at the request of Dr. Carrington. A few days before his first visit he found a painless lump under the left nipple in the shower and thought at first that it was the breast enlargement he had as a boy. Diagnostic mammography and ultrasound of both breasts and both axillae five days ago showed a 1.6 cm irregular retroareolar mass on the left and one abnormal left axillary node, with a normal right breast and axilla. Core biopsies of both show invasive ductal carcinoma, grade 3, ER 95 percent, PR 85 percent, HER2 1+, Ki-67 30 percent, with metastatic carcinoma in the node. He has no bone pain, cough, headache, or weight loss. He is fit, trains most days, and works as an actor. He says he did not know a man could get breast cancer, and he is worried about privacy at work. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; anxious but composed |
| Breasts | Left: 1.5 cm firm, irregular mass eccentric to the nipple at 2 o'clock, not fixed to the chest wall or skin; no nipple retraction or discharge. Right: no mass and no glandular enlargement |
| Lymph nodes | One firm, mobile 1 cm left axillary node; no right axillary, supraclavicular, or cervical nodes |
| Musculoskeletal | Full shoulder movement on both sides |

BP 134/82 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 99% on room air; weight 85.6 kg; BMI 24.2 kg/m². All vital signs are synthetic.

## Data reviewed

Diagnostic mammography and ultrasound of both breasts and both axillae; core biopsy pathology of the breast mass and the axillary node with ER, PR, HER2, and Ki-67; today's preoperative blood count and chemistry, all normal. Hemoglobin: 14.8 g/dL; White cell count: 6.6 10*3/uL; Absolute neutrophil count: 3.9 10*3/uL; Platelets: 246 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 1.02 mg/dL; eGFR: 89 mL/min/1.73 m²; Glucose: 92 mg/dL; Calcium: 9.5 mg/dL; ALT: 24 U/L; AST: 22 U/L; Alkaline phosphatase: 71 U/L; Total bilirubin: 0.7 mg/dL; Albumin: 4.4 g/dL; PHQ-9: 5. All results are synthetic.

## Assessment

1. **Invasive ductal carcinoma of the left breast, clinical stage IIA (cT1c cN1 M0), ER and PR positive, HER2 negative, grade 3** (C50.122). Men get breast cancer. In men it is usually retroareolar, as here, and usually hormone receptor-positive. He has early, operable disease with a biopsy-proven axillary node. Staging scans are not recommended for clinical stage IIA without symptoms or abnormal blood tests. Because the tumor is small and hormone receptor-positive, surgery first is reasonable; chemotherapy before surgery was discussed as an alternative, and surgery first gives the full pathology to guide treatment afterwards. With so little breast tissue in men, mastectomy is the usual operation, and with a biopsy-proven node, a level I and II axillary dissection is standard. **S**
2. **Germline testing**. Germline testing should be offered to every man with breast cancer. BRCA2 is the gene most often found. A variant would raise the risk of a new cancer in the other breast and of prostate and pancreatic cancer, and would matter for his relatives. It need not delay surgery, because the operation on the cancer side is the same either way. **S**
3. **Concern about privacy and stigma**. He feels embarrassed by a breast cancer diagnosis and fears it could cost him work. These are common reasons men delay care or keep it secret. He came in promptly, which is the right thing, and his care can be kept confidential. **S**

## Recommendations

1. Left total mastectomy with level I and II axillary lymph node dissection in two days.
2. Removal of the other breast is not needed for cancer control; some men choose it for symmetry, and that choice is his. It does not need to wait for the germline result. Reconstruction is possible but rarely chosen by men; offered.
3. No staging CT, bone scan, or PET before surgery.
4. Genetic counseling and a germline multigene panel (BRCA2, BRCA1, PALB2, CHEK2, ATM, and others), sent today.
5. Measure both upper arms before surgery as the lymphedema baseline.
6. After surgery: a drain for about a week, shoulder exercises from the first day, numbness under the arm is expected, and lymphedema risk reduction for the left arm.
7. Medical oncology after the pathology, to plan chemotherapy and endocrine therapy; tamoxifen is the first-choice endocrine therapy for men. Radiation oncology review if two or more nodes, or other high-risk features, are found.

## Strengths and supports

- Supports: close friends and family; wants the diagnosis kept private for now **S**

## Communication

Discussed with Dr. Carrington today. The patient agrees with the plan and asked for his records to be kept confidential; written information about breast cancer in men was given. **S**

## Follow-up

Operation in two days. Surgical review of the wound and pathology in about ten days. Medical oncology after the pathology. Primary care continues distress screening and preventive care before treatment. **S**

## Guideline basis

- Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020), American Society of Clinical Oncology
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024), American Society of Clinical Oncology and Society of Surgical Oncology
- Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016), American Cancer Society and American Society of Clinical Oncology
